Ictal Adipokines Are Associated with Pain Severity and Treatment Response in Episodic Migraine

Overview

Journal Neurology

Specialty Neurology

Date 2015 Mar 10

PMID 25746563

Citations 12

Authors

Nu Cindy Chai

Bizu Gelaye

Gretchen E Tietjen

Paul D Dash

Barbara A Gower

Linda W White

Thomas N Ward

Ann I Scher

B Lee Peterlin

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate ictal adipokine levels in episodic migraineurs and their association with pain severity and treatment response.

Methods: This was a double-blind, placebo-controlled trial evaluating peripheral blood specimens from episodic migraineurs at acute pain onset and 30 to 120 minutes after treatment with sumatriptan/naproxen sodium vs placebo. Total adiponectin (T-ADP), ADP multimers (high molecular weight [HMW], middle molecular weight, and low molecular weight [LMW]), leptin, and resistin levels were evaluated by immunoassays.

Results: Thirty-four participants (17 responders, 17 nonresponders) were included. In all participants, pretreatment pain severity increased with every quartile increase in both the HMW:T-ADP ratio (coefficient of variation [CV] 0.51; 95% confidence interval [CI]: 0.08, 0.93; p = 0.019) and resistin levels (CV 0.58; 95% CI: 0.21, 0.96; p = 0.002), but was not associated with quartile changes in leptin levels. In responders, T-ADP (CV -0.98; 95% CI: -1.88, -0.08; p = 0.031) and resistin (CV -0.95; 95% CI: -1.83, -0.07; p = 0.034) levels decreased 120 minutes after treatment as compared with pretreatment. In addition, in responders, the HMW:T-ADP ratio (CV -0.04; 95% CI: -0.07, -0.01; p = 0.041) decreased and the LMW:T-ADP ratio (CV 0.04; 95% CI: 0.01, 0.07; p = 0.043) increased at 120 minutes after treatment. In nonresponders, the LMW:T-ADP ratio (CV -0.04; 95% CI: -0.07, -0.01; p = 0.018) decreased 120 minutes after treatment. Leptin was not associated with treatment response.

Conclusions: Both pretreatment migraine pain severity and treatment response are associated with changes in adipokine levels. Adipokines represent potential novel migraine biomarkers and drug targets.

Citing Articles

Altered immunity in migraine: a comprehensive scoping review.

Ha W, Chu M J Headache Pain. 2024; 25(1):95.

PMID: 38844851 PMC: 11157828. DOI: 10.1186/s10194-024-01800-8.

Biomarkers of Migraine: An Integrated Evaluation of Preclinical and Clinical Findings.

Demartini C, Francavilla M, Zanaboni A, Facchetti S, De Icco R, Martinelli D Int J Mol Sci. 2023; 24(6).

PMID: 36982428 PMC: 10049673. DOI: 10.3390/ijms24065334.

The effects of nano-curcumin supplementation on adipokines levels in obese and overweight patients with migraine: a double blind clinical trial study.

Sedighiyan M, Abdolahi M, Jafari E, Vahabi Z, Athar S, Hadavi S BMC Res Notes. 2022; 15(1):189.

PMID: 35606882 PMC: 9125853. DOI: 10.1186/s13104-022-06074-4.

Assessment of Alteration of Serum Adiponectin Levels in Migraineurs: An Interventional Case Control Study.

Joshi S, Nemichandra S, Harsha S, Prashant A, Paneyala S, Iqbal R Ann Neurosci. 2021; 27(3-4):148-152.

PMID: 34556953 PMC: 8455013. DOI: 10.1177/0972753121990141.

Diagnostic Accuracy of Serum Calcitonin Gene-Related Peptide and Apolipoprotein E in Migraine: A Preliminary Study.

Latif R, Rafique N, Al Asoom L, Alsunni A, Mohammed Salem A, AlNoaimi D Int J Gen Med. 2021; 14:851-856.

PMID: 33737829 PMC: 7966296. DOI: 10.2147/IJGM.S303350.

References

Nagaev I, Bokarewa M, Tarkowski A, Smith U . Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes. PLoS One. 2006; 1:e31. PMC: 1762367. DOI: 10.1371/journal.pone.0000031. View

Bernecker C, Pailer S, Kieslinger P, Horejsi R, Moller R, Lechner A . GLP-2 and leptin are associated with hyperinsulinemia in non-obese female migraineurs. Cephalalgia. 2010; 30(11):1366-74. DOI: 10.1177/0333102410364674. View

Kadowaki T, Yamauchi T . Adiponectin and adiponectin receptors. Endocr Rev. 2005; 26(3):439-51. DOI: 10.1210/er.2005-0005. View

Peterlin B, Bigal M, Tepper S, Urakaze M, Sheftell F, Rapoport A . Migraine and adiponectin: is there a connection?. Cephalalgia. 2007; 27(5):435-46. DOI: 10.1111/j.1468-2982.2007.01306.x. View

Bedaiwy M, Falcone T, Goldberg J, Sharma R, Nelson D, Agarwal A . Peritoneal fluid leptin is associated with chronic pelvic pain but not infertility in endometriosis patients. Hum Reprod. 2005; 21(3):788-91. DOI: 10.1093/humrep/dei376. View

Considine R, Sinha M, Heiman M, Kriauciunas A, STEPHENS T, Nyce M . Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996; 334(5):292-5. DOI: 10.1056/NEJM199602013340503. View

Peterlin B, Tietjen G, Gower B, Ward T, Tepper S, White L . Ictal adiponectin levels in episodic migraineurs: a randomized pilot trial. Headache. 2013; 53(3):474-90. PMC: 3601586. DOI: 10.1111/head.12071. View

Lippi G, Meschi T, Mattiuzzi C, Borghi L, Targher G . Adiponectin and migraine: systematic review of clinical evidence. Neurol Sci. 2014; 35(8):1167-71. DOI: 10.1007/s10072-014-1719-3. View

Tilg H, Moschen A . Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006; 6(10):772-83. DOI: 10.1038/nri1937. View

10.

Schutt M, Brinkhoff J, Drenckhan M, Lehnert H, Sommer C . Weight reducing and metabolic effects of topiramate in patients with migraine--an observational study. Exp Clin Endocrinol Diabetes. 2010; 118(7):449-52. DOI: 10.1055/s-0030-1248289. View

11.

Mantzoros C, Magkos F, Brinkoetter M, Sienkiewicz E, Dardeno T, Kim S . Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab. 2011; 301(4):E567-84. PMC: 3191548. DOI: 10.1152/ajpendo.00315.2011. View

12.

Shand B, Elder P, Scott R, Frampton C, Willis J . Biovariability of plasma adiponectin. Clin Chem Lab Med. 2006; 44(10):1264-8. DOI: 10.1515/CCLM.2006.227. View

13.

Avraham Y, Davidi N, Lassri V, Vorobiev L, Kabesa M, Dayan M . Leptin induces neuroprotection neurogenesis and angiogenesis after stroke. Curr Neurovasc Res. 2011; 8(4):313-22. DOI: 10.2174/156720211798120954. View

14.

Chai N, Bond D, Moghekar A, Scher A, Peterlin B . Obesity and headache: Part II--potential mechanism and treatment considerations. Headache. 2014; 54(3):459-71. PMC: 3975621. DOI: 10.1111/head.12297. View

15.

Maffei M, Halaas J, Ravussin E, Pratley R, Lee G, Zhang Y . Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med. 1995; 1(11):1155-61. DOI: 10.1038/nm1195-1155. View

16.

Lei L, Yuan X, Wang S, Zhang F, Han Y, Ning Q . Mitogen-activated protein kinase pathways are involved in the upregulation of calcitonin gene-related peptide of rat trigeminal ganglion after organ culture. J Mol Neurosci. 2012; 48(1):53-65. DOI: 10.1007/s12031-012-9772-y. View

17.

Jamaluddin M, Yan S, Lu J, Liang Z, Yao Q, Chen C . Resistin increases monolayer permeability of human coronary artery endothelial cells. PLoS One. 2014; 8(12):e84576. PMC: 3874001. DOI: 10.1371/journal.pone.0084576. View

18.

Park H, Ahima R . Resistin in rodents and humans. Diabetes Metab J. 2014; 37(6):404-14. PMC: 3881324. DOI: 10.4093/dmj.2013.37.6.404. View

19.

Rajala M, Lin Y, Ranalletta M, Yang X, Qian H, Gingerich R . Cell type-specific expression and coregulation of murine resistin and resistin-like molecule-alpha in adipose tissue. Mol Endocrinol. 2002; 16(8):1920-30. DOI: 10.1210/me.2002-0048. View

20.

BANKS A, Davis S, Bates S, Myers Jr M . Activation of downstream signals by the long form of the leptin receptor. J Biol Chem. 2000; 275(19):14563-72. DOI: 10.1074/jbc.275.19.14563. View